1 / 5

Summary of Design

Summary of Design. Aim : Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design : Randomized double blind, 2x2 factorial, People with high CV risk, exclusion: macroalbuminuria, s-creatinine > 2.3 mg/dl

bathsheba
Download Presentation

Summary of Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double blind, 2x2 factorial, People with high CV risk, exclusion: macroalbuminuria, s-creatinine > 2.3 mg/dl Size: 9541 patients followed for 4 to 6 years: Organization: 267 hospitals from 19 countries in North & South America and Europe, Coordinated by the CCC at McMaster University, Hamilton, Canada Principal investigator: S . Yusuf, Coordinator Europe: J Mann, J Ostergren, B. Wolfenbuttel

  2. G E R Gerstein, Mann, Yusuf, JAMA 2001; 286: 421 - 8

  3. ACR and future development of clinical proteinuria / overt nephropathy Baseline microalbuminuria was associated with the development of clinical proteinuria in: Diabetes: 20.1 % / 4 years No diabetes: 4.9 % / 4 years In those with microalbuminuria, the risk was 17 - 20-fold higher than in those without (p<0.0001 after adjusting for all risk factors monitored in HOPE)

  4. Progression of Albuminuria: MA  ON or None  MA/ON Ramipril Placebo N (%) N (%) All patients 909 (19) 1032 (22) RR (95% CI) 0.88 (0.81-0.96) p = 0.0056 MA: microalbuminuria ON: overt nephropathy

  5. Serum creatinine in all diabetic patients, and in diabetics with renal insufficiency (RI) N = 333 Serum creatinine (mg/dl) Mann, Gerstein, et al, Ann Int Med 2002 N = 3,571 years

More Related